The growing field of immune metabolism has revealed promising indications for metabolic
targets to modulate anti-cancer immunity. Combination therapies involving metabolic …

Currently, a marked number of clinical trials on cancer treatment have revealed the success
of immunomodulatory therapies based on immune checkpoint inhibitors that activate tumor …

There has been significant progress in utilizing our immune system against cancer, mainly
by checkpoint blockade and T cell-mediated therapies. The field of cancer immunotherapy is …

The development of immunotherapies over the past decade has resulted in a paradigm shift
in the treatment of cancer. However, the majority of patients do not benefit from …

Tumor cells reprogram nutrient acquisition and metabolic pathways to meet their energetic,
biosynthetic, and redox demands. Similarly, metabolic processes in immune cells support …

Immune checkpoint inhibitors (ICIs) targeting immune checkpoint proteins, such as CTLA-4
and PD-1/PD-L1, have demonstrated remarkable and durable clinical responses in various …

Immunotherapy shifted the paradigm of cancer treatment. The clinical approval of immune
checkpoint blockade and adoptive cell transfer led to considerable success in several tumor …

Tumor-induced immune tolerance permits growth and spread of malignant cells. Cancer
cells have strong influence on surrounding cells and shape the hypoxic tumor …

The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-
mediated control of tumor growth. Interruption of one or more steps of the CIC enables …

Mounting evidence has revealed that the therapeutic efficacy of immunotherapies is
restricted to a small portion of cancer patients. A deeper understanding of how metabolic …